Nuvectis Pharma
NVCT
48 hedge funds and large institutions have $32M invested in Nuvectis Pharma in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 26 increasing their positions, 8 reducing their positions, and 8 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 8
55% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $724K
44% more capital invested
Capital invested by funds: $22.2M → $32M (+$9.79M)
2.03% more ownership
Funds ownership: 14.51% → 16.55% (+2%)
9% less funds holding
Funds holding: 53 → 48 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$1.18M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$957K |
| 3 |
BlackRock
New York
|
+$635K |
| 4 |
OCM
Occam Crest Management
Darien,
Connecticut
|
+$587K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$258K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$196K |
| 3 |
Jane Street
New York
|
-$171K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$141K |
| 5 |
Goldman Sachs
New York
|
-$122K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Two Sigma Investments
New York
| – | -$111K | -18,435 | Closed |
|
|
XT
52
XTX Topco
George Town,
Cayman Islands
| – | -$89.5K | -14,866 | Closed |
|
53
Marshall Wace
London,
United Kingdom
| – | -$64.4K | -10,693 | Closed |
|
|
EWA
54
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$458 | -76 | Closed |
|
|
AAP
55
Arax Advisory Partners
Denver,
Colorado
| – | -$229 | -38 | Closed |
|
56
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$13 | -2 | -6% |
|
NVCT Hedge Fund Activity: Q4 2025 in Review
48 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2025, worth a combined $32M — up 44% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NVCT and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 26 added.
The largest buyer was Iridian Asset Management, adding an estimated $1.18M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $258K sold.
- 48 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2025, down from 53 in Q3 2025.
- Funds reported $32M of Nuvectis Pharma stock for Q4 2025, up 44% quarter-over-quarter.
- 3 funds opened new Nuvectis Pharma positions in Q4 2025 and 8 closed out, a net change of -5 holders.
- The largest Nuvectis Pharma buyer in Q4 2025 was Iridian Asset Management, an estimated $1.18M added.
- The largest Nuvectis Pharma seller in Q4 2025 was Renaissance Technologies, an estimated $258K sold.
Based on aggregated 13F filings for Q4 2025.